Global Bispecific Antibodies for Cancer Market 2019-2023
About this market
The advantages of bispecific antibodies over monoclonal antibodies is one of the key factors expected to propel the market growth during the forecast period. The limitations of monoclonal antibodies such as limited binding abilities for specific antigens have encouraged researchers to improve and increase the efficacy of the molecules and enhance their function by developing antibodies with two or more targets. Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy. Hence, the advantages of bispecific antibodies will drive the growth of the market in the upcoming years. Technavio’s analysts have predicted that the bispecific antibodies for cancer market will register a CAGR of over 30% by 2023.
Increasing prevalence of cancer
The increase in the prevalence of cancer across the world will fuel the demand for bispecific antibodies to treat these cancers, thereby driving the growth of the market.
The high cost of drug
Most of the cancer patients in low- and middle-income countries fail to complete the course of drug therapy as these drugs are priced beyond their reach.
For the detailed list of factors that will drive and challenge the growth of the bispecific antibodies for cancer market during 2019-2023, view our report.
The market appears to be moderately fragmented with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Technavio Announces the Publication of its Research Report – Global Bispecific Antibodies for Cancer Market 2019-2023
Technavio recognizes the following companies as the key players in the global bispecific antibodies for cancer market: Amgen Inc., Astella Pharma Inc., Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd., Merus, and Regeneron Pharmaceuticals, Inc.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the emerging bispecific antibody generation platforms.”
According to the report, one of the major drivers for this market is the advantages of bispecific antibodies over monoclonal antibodies.
Further, the report states that one of the major factors hindering the growth of this market is the side effects of BLINCYTO.
Amgen Inc.Astella Pharma Inc.Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.MerusRegeneron Pharmaceuticals, Inc.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook